To the best of our knowledge, APOA2 has been identified as one of the most significant DEPs in nasopharyngeal carcinoma (NPC) for the first time, underscoring its potential as a novel biomarker for this complex disease. The gene discussed is APOA2; the disease is nasopharyngeal carcinoma.